Overview
This study aims to evaluate the impact of Sodium-dependent glucose transporters 2 inhibitor Empagliflozin on the exercise capacity,symptoms of heart failure, cardiac function, myocardial remodeling and quality of life of nonobstructive HCM patients with HFpEF.
Eligibility
Inclusion Criteria:
- Patients with a diagnosis of nonobstructive hypertrophic cardiomyopathy;
- At least 18 years old;
- LVEF≥50%
- Elevated NT-proBNP >300 pg/ml for patients without atrial fibrillation (AF), or >900 pg/ml for patients with AF at Visit 1;
- NYHA II-IV
- Capable of performing cardiopulmonary exercise test with an RER≥1.0
- Signed and dated written informed consent and willing to return for clinical follow-up.
Exclusion Criteria:
- Under-went septal reduction therapy within 3 months before screening;
- Acute decompensation heart failure within 3 months before screening;
- Symptomatic low BP or SBP<100mmHg;
- eGFR<30ml/min/1.73m2
- LVOTG ≥30mmHg at rest or under provocation;
- Renal insufficiency with eGFR<50mL/min/1.73m2
- ICD implantation or CRT planned within 3 months;
- Women who are pregnant, or who plan to become pregnant while in the trial;
- Currently enrolled in another investigational device or drug trial;
- Combining any other clinical condition with a life expectancy less than 1 year.